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Blood pressure reduction initiates the antiproteinuric effect of ACE
inhibition. Several observations question the role of blood pressure and
renal hemodynamic changes in the long-term antiproteinuric effect of
ACE inhibition. To differentiate blood pressure and renal effects in the
initial antiproteinuric response, the placebo-controlled acute effects of the
ACE inhibitor enalaprilat (10 mg iv.) on blood pressure, renal hemody-
namics, and proteinuria were compared with those of nitroprusside in nine
patients with non-diabetic proteinuria. In addition, we studied whether an
exogenous angiotensin II infusion reverse the initial enalaprilat-induced
antiproteinuric response. Enalaprilat and nitroprusside reduced MAP by
—11.3 2.4% and —14.1 2.3%, respectively, whereas only enalaprilat
showed renal hemodynamic effects, reflected by an increase in ERPF of
18.4 5.4% and a decrease in FF of —17.1 2.6%. Despite the
contrasting renal hemodynamic profiles, enalaprilat (—10.6 4.8%) and
nitroprusside (—12.8 5.1%) equally decreased proteinuria. Exogenous
infusion of angiotensin II completely reversed the blood pressure reduc-
tion and renal efferent vasodilatation induced by enalaprilat. Proteinuria
also increased by 13.1 7.8% to placebo level, albeit statistically
non-significant. We conclude that the initial antiproteinuric effect of ACE
inhibition appears to be mediated by blood pressure reduction and does
not require its specific renal hemodynamic effect. Further studies should
clarify whether the renal efferent vasodilatation during ACE inhibition is
required to gradually induce renal structural changes that prevent the
abundant passage of proteins.
Although the capacity of ACE inhibitors to lower blood pres-
sure is comparable to that of other antihypertensives, long-term
treatment with ACE inhibition results in a 40 to 50% lowering of
proteinuria, whereas other antihypertensive agents have a slight
or no effect on proteinuria [1—4]. Many studies have tried to
clarify the mechanism involved in this additional reduction of
proteinuria by ACE inhibitors. At first, the renal efferent vasodi-
latation characteristic of ACE inhibition was held responsible
[5—91. Several of the following observations question the role of
renal hemodynamic changes in the long-term antiproteinuric
effect of ACE inhibition. First, the antiproteinurie effect has a
slow onset reaching a maximum approximately four weeks after
start of treatment, whereas the blood pressure and renal hemo-
dynamic effect appear maximal already after several hours of
ACE-inhibition [101. Second, the blood pressure and renal hemo-
dynamic changes after three months of ACE inhibition can be
completely reversed by acute exogenous angiotensin II, whereas
the antiproteinuric response is unaffected [11]. These data suggest
that both blood pressure and renal hemodynamic factors play a
minor role in the antiproteinuric effect at least during long-term
ACE inhibition.
The acute lowering of proteinuria by ACE inhibitors, however,
may well be explained by their concomitant blood pressure or
renal hemodynamic changes. Several reports in non-diabetic [10,
12] and diabetic renal disease [13, 14] showed the 15 to 20%
reduction of proteinuria after a single dose of an ACE inhibitor to
be related to changes in blood pressure and/or renal hemodynam-
ics. The magnitude of the acute antiproteinuric response to ACE
inhibition is well comparable to that of the long-term reduction of
proteinuria by other antihypertensives. It may therefore be hy-
pothesized that blood pressure reduction, rather than renal
hemodynamic changes, mediates the acute small reduction of
proteinuria by ACE inhibitors, whereas the long-term more
marked reduction is governed by non-hemodynamic factors. To
date, no study has been performed evaluating the causal role of
blood pressure reduction and/or that of renal hemodynamic
effects in the acute antiproteinuric response of ACE inhibition.
Since it has been demonstrated in rat models that exogenous
angiotensin II infusion or increased levels of endogenous angio-
tensin II are able to increase urinary protein loss in parallel with
increases in blood pressure and renal efferent vasoconstriction
[15—19j, it may be hypothesized that the acute, hemodynamically
mediated antiproteinuric response of ACE inhibition can well be
reversed by angiotensin II.
In the present study, we therefore compared the acute effects of
the ACE inhibitor enalapril on proteinuria, blood pressure, and
renal hemodynamics to those of nitroprusside. To study the
importance of the renin-angiotensin system (RAS) in the acute
response to ACE inhibition, we furthermore tested whether the
acute antiproteinuric effect of enalapril could be reversed by an
infusion of exogenous angiotensin II.
Methods
Patients and protocol
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Nine non-diabetic patients with chronic renal disease were
enrolled in this study. Entry criteria were stable proteinuria
exceeding 3.0 g/day, a stable creatinine clearance of 50 m1 min
or more, and a diastolic blood pressure of less than 110 mm Hg.
Patients with diabetes mellitus, edema, or renovascular hyperten-
sion were excluded. Before entry all antihypertensive drugs were
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Fig. 1. Study protocol.
withdrawn for at least four weeks, except for one patient who
needed diuretic treatment to avoid edema. The responses in this
patient were not different from the other patients. All patients
adhered to a 100 mmol sodium restricted diet. The study was
approved by the local Medical Ethical Committee and all subjects
gave their informed consent to participate in this study.
Patients underwent four in-hospital renal function assessments
once weekly during four weeks. One 24-hour urine collection was
performed the day before each visit. During the study day patients
remained in supine position, except when voiding. A bolus
injection of renal function tracers was administered at 8:00 hours
followed by a constant infusion of these tracers in the right
antecubital vein. At 8:30 hours the patients received their regular
breakfast, whereafter 150 mI/hr of beverages were permitted,
except for coffee. After a two-hour equilibration period to 10:00
hours, in which a constant plasma level of renal function tracers
was obtained, two one-hour baseline clearance measurements
were performed from 10:00 to 12:00 hours. At day A patients
received an intravenous bolus of placebo (dextrose 5%) at 12:00
hours, followed by a continuous placebo infusion from 12:00 to
17:00 hours. At day B enalaprilat (10 mg i.v.) was given at 12:00
hours, followed by a continuous placebo infusion from 12:00 to
17:00 hours. At day C a continuous intravenous infusion of
nitroprusside was administered from 12:00 to 17:00 hours, titrated
between 12:00 and 12:30 hours to obtain a hypotensive effect
comparable to that of enalaprilat in each patient. At day D
patients again received enalaprilat (10 mg i.v.) at 12:00 hours,
followed by a continuous placebo infusion from 12:00 to 17:00
hours, and a concomitant continuous exogenous angiotensin II
infusion from 14:30 to 17:00 hours. The dose of exogenous
angiotensin II was titrated between 14:30 and 15:00 hours to
increase blood pressure to placebo level in each patient. Study
days A and B as well as C and D were performed in a random
cross-over and single-blinded order. A 30-minute placebo titration
was performed when appropriate between 12:00 and 12:30, as well
as between 14:30 and 15:00 hours, to assure a uniform study day
design (Fig. 1). The total amount of infused fluids was 150 mI/hr.
Blood pressure was measured every five minutes during the
clearance periods and every two minutes during the two 30
minutes titration intervals. Blood and urine samples were ob-
tained for determination of renal hemodynamic parameters and
proteinuria during each clearance period. At 12:00, 14:30, and
17:00 hours blood was drawn for determination of plasma renin
activity (PRA), ACE, and angiotensin II.
After completion of the study protocol, all but one patient were
admitted to prolonged treatment with the ACE inhibitor enalapril
10 mg o.i.d. Blood pressure, creatinine clearance and proteinuria
were measured after 1, 7 and 28 days of treatment.
Clinical and laboratory procedures
Serum and urine electrolytes, urea and creatinine were deter-
mined with an automated multi-analyzer (SMA-C, Technicon®),
while urinary protein concentration was determined with the
pyrogallol red-molybdate method [201. The intra-assay coefficient
of variation of this method is less than 3.3%, while the inter-assay
coefficient of variation is less than 3.0%. Blood pressure was
recorded with an automated device (Dinamap®). Mean arterial
pressure was calculated as the sum of one-third of the systolic and
two-thirds of the diastolic blood pressure. The mean blood
pressure during each one-hour clearance period was used for data
analysis. GFR and ERPF were measured by a constant infusion of
1251-iothalamate and 1311-hippuran, respectively [21]. The intra-
patient day-to-day coefficient of variation of this method is 2.2%
for GFR and 5.0% for ERPF. Filtration fraction was calculated as
the ratio of GFR and ERPF. Renal vascular resistance (RVR)
was defined as MAP divided by ERPF. Serum ACE was measured
using an HPLC-assisted assay [22]. PRA was assessed by the
quantification of generated angiotensin I as measured by radio-
immunoassay (Rianen® angiotensin I RIA kit). Blood for the
determination of angiotensin II was collected in prechilled glass
tubes containing 1,10-phenantroline, EDTA, enalaprilat and neo-
mycin to prevent in vitro generation of angiotensin II. Blood was
immediately centrifuged at 4°C and plasma samples were stored at
—20°C until analysis. Angiotensin II was determined using the
Nichols Institute Diagnostics Angiotensin II radioimmunoassay
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Table 1. Patient characteristics at entry
Patient Gender
Age
years
Renal
diagnosis
Blood
pressure
mm Hg
Creatinine
clearance
ml min'
Proteinuria
g/day
1 M 30 FSGS 143/96 108 18.6
2 M 43 IgA 160/95 80 3.0
3 F 40 FSGS 116/74 71 5.6
4 M 62 FSGS 118/78 110 7.0
5 M 32 FSGS 145/91 47 5.5
6 M 32 IgA 122/77 93 4.0
7 M 44 MGP 132/81 165 12.1
8 M 59 MGP 139/87 104 7.8
9 M 39 MGP 119/70 82 3.4
Mean 42 133/83 96 7.4
SE 4 5/3 Ii 1.7
Abbreviations are: F, female; M, male; FSGS, focal segmental glomer-
ulosclerosis; IgA, IgA nephropathy; MGP, membranous glomerulopathy.
with an inter-assay variation of 5.1% and an intra-assay variation
of 4%. The lower detection range is 3.6 pg• m1'.
Data analysis
Data are expressed as mean standard error (SE), unless
otherwise indicated. The effects of placebo, enalaprilat, nitroprus-
side, and angiotensin II during enalaprilat were tested as the
percentage change from the mean of the two one-hour baseline
values. To exclude the influence of circadian variation of the
various parameters, the response to enalaprilat, nitroprusside,
and angiotensin II during enalaprilat were also tested against the
time corresponding placebo response. Statistical analysis was
performed using a paired, non-parametric ANOVA (Friedmann)
for repeated measurements or a paired Wilxocon's signed rank
test. Correlations were calculated by Spearman's linear regression
analysis. Statistical significance was assumed at a 5% level.
Results
Patient characteristics at entry are given in Table 1. None of the
patients had signs of peripheral edema. None of the study
parameters showed significant differences during the baseline
clearance periods on each of the study days as shown in Table 2.
Proteinuria, daily urinary excretion of sodium and urea, and body
weight remained stable during the entire study period. Figure 2
shows the percentage change from baseline for each of the study
parameters after infusion of placebo, enalaprilat, nitroprusside as
well as angiotensin II during enalaprilat. The influence of the
interventions on parameters of the renin-angiotensin system are
given in Table 3.
Placebo
During placebo infusion no significant changes in ACE, PRA,
and angiotensin II were observed. MAP increased from 103 2
to 109 4 mm Hg (P < 0.01). Although GFR and ERPF did not
change, filtration fraction increased from 20.7 1.2% to 21.9
1.8% (P < 0.01), and RVR increased from 27.3 3.7 to 30.2
5.5 10—2 mm Hg• m1 min1 (P < 0.01). Urinary protein excre-
tion fell from 0.25 0.03 to 0.23 0.05 g hr' (P < 0.05).
Fractional sodium excretion did not change significantly.
Table 2. Baselinc characteristics at each of the study days
Baseline
Baseline
PLA
Baseline
ENA
Baseline
NIP
ENA +
Ang II
Urinary sodium 103 15 104 16 106 18 112 20
excretion
mmol/day
Urinary urea 301 36 303 58 322 33 325 46
excretion
mmol/day
Proteinuriag/day 7.8 1.4 7.0 1.2 7.6 1.1 7.2 1.6
Body weight kg 79.6 3.3 79.3 3.1 79.4 3.3 79.4 3.3
MAP mm Hg 103 2 103 3 102 2 102 3
GFR ml min' 91.9 7.0 92.3 6.5 91.9 7.3 95.8 7.9
ERPFmImIn' 477±50 477±45 490±51 486±47
FF % 20.7 1.2 20.5 1.1 20.1 1.1 20.8 1.2
RVR 1O_2 mm 27.3 3.7 26.7 3.8 26.7 3.9 26.2 3.6
Hg-minml
Proteinuria 0.25 0.03 0.30 0.04 0.26 0.03 0.28 0.04
g hr'
The upper part contains parameters measured in the 24-hour urine
collection. The bottom part contains parameters of the study day. Abbre-
viations are: PLA, placebo; ENA, enalaprilat; NIP, nitroprusside; Ang II,
angiotensin II; MAP, mean arterial pressure; GFR, glomerular filtration
rate; ERPF, effective renal plasma flow; FF, filtration fracton; RVR, renal
vascular resistance.
Enalaprilat
Infusion of 10 mg enalaprilat induced a complete inhibition of
ACE (P < 0.05), an increase in PRA (P < 0.05), and a decrease
in angiotensin II (P < 0.05). MAP lowered from 103 3 to 95
3 mm Hg (P < 0.01). ERPF increased from 477 45 to 532 73
ml- min' (P < 0.05). Since GFR non-significantly fell from 92.3
6.5 ml -min1 to 89.9 9.7 ml min1, FF decreased from 20.5
1.1% to 18.2 1.7% (P < 0.05). RVR decreased from 26.7
3.8 to 21.7 4.4 10—2mm Hg ml- min' (P < 0.01). Proteinuria
fell from 0.30 0.04 to 0.24 0.05 g hr1 (P < 0.01). Fractional
sodium excretion did not change significantly from baseline.
When compared to placebo, enalaprilat induced a decrease in
MAP (P = 0.004), FF (P = 0.004), RVR (P = 0.004), proteinuria(P = 0.05), and an increase in ERPF (P = 0.004), and fractional
sodium excretion (P = 0.01). In patients number 4 and 6
enalaprilat did not decrease proteinuria compared to placebo.
Nitroprusside
Infusion of nitroprusside (0.46 0.14 .tg kg1 min ')had no
effect on ACE, PRA, or angiotensin II levels. It resulted in a
lowering of MAP from 102 2 to 91 2 mm Hg (P < 0.001).
Although GFR and ERPF did not significantly change, filtration
fraction increased from 20.1 1.1% to 21.2 1.6% (P < 0.05).
RVR decreased from 26.7 5.8 to 24.2 4.5 10—2 mm
Hg - ml min (P < 0.05). Proteinuria also decreased during
nitroprusside from 0.26 0.03 to 0.20 0.04 g - hr' (P < 0.05).
In comparison to placebo, nitroprusside induced a decrease in
MAP (P = 0.004), RVR (P = 0.004), proteinuria (P = 0.02), and
fractional sodium excretion (P = 0.03). In comparison to enala-
prilat, nitroprusside induced a slightly greater decrease in MAP
(P < 0.05), and a smaller decrease in RVR (P < 0.05). Those two
patients who showed no antiproteinuric response to acute ACE
inhibition also had the lowest antiproteinuric response to nitro-
prusside.
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Angiotensin II during enalaprilat
The repeated enalaprilat infusion induced similar responses
of all parameters as the previous enalaprilat infusion (Fig. 2).
The two patients who had no antiproteinuric response to the
first enalaprilat infusion did again fail to respond during the
second. Concomitant infusion of angiotensin II (2.4 1.0
ng kg1 .min1) during the last two clearance periods com-
pletely abolished the enalaprilat-induced increase in PRA and
decrease in angiotensin II (P < 0.05). MAP increased from 94
3 mm Hg during enalaprilat to 110 4 mm Hg during the
concomitant angiotensin II infusion (P < 0.01). GFR increased
from 93.0 10.7 to 100,5 11.9 ml min1 (P < 0.05), ERPF
17 11 13 15
Time, hours
Fig. 2. The acute effects of placebo (—•),
enalaprilat (Q—CJ), nitroprusside (U •),
and angiotensin II during enalaprilat (A—A)
on mean arterial pressure (MAP), glomerular
filtration rate (GFR), effective renal plasma flow
(ERPF), filtration fraction (FF), renal vascular
resistance (RVR), and proteinuria
Parameters are expressed as percentage change
17 from the mean of two one-hour baseline values.
Data are given as mean SE.
decreased from 559 78 to 412 55 ml min1 (P < 0.01), and
as a consequence FF increased from 18.1 1.8% to 24.4 2.3%
(P < 0.01). RVR increased from 20.9 4.1 to 31.5 5.1 102 mm
Hg ml min1 (P < 0.01) and fractional sodium excretion fell
from 6.66 0.99 to 3.44 0.88 mmol hr1 (P < 0.01).
Angiotensin II increased proteinuria from 0.23 0.05 to 0.26
0.05 g hr . In comparison to placebo, angiotensin II decreased
ERPF (P = 0.008) and fractional sodium clearance (P = 0.008),
and increased FF (P 0.02) and RVR (P =0.008). In comparison
to enalaprilat without a concomitant angiotensin II infusion,
angiotensin II increased MAP (P = 0.004), FF (P = 0.004) and
RVR (P = 0.004), and decreased ERPF (P = 0.004) and
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TabJe 3. Parameters of the renin-angiotensin system at each of the
study days
Time
hr PLA ENA NIP
ENA +
Ang II
ACE 12:00 24.2 4.0 24.3 3.0 27.0 3.3 22.0 3.2
Uliter' 14:30
17:00
20.1 3.0
21.3 2.9
1.7 0.2a
2.4 0.2a
25.0 2.8
25.9 3.4
1.7 0.2
3.1 0.6
PRAAngIliter' 12:0014:30 1.6 0.21.6 0.4 1.9 0.37.9 59U 1.9 0.52.4 0.4 1.9 0.46.7 4.6ahr' 17:00 1.5 0.4 5.8 39U 2.1 0.3 1.7 0•4h
Ang II
pgml'
12:00
14:30
17:00
19 3
17±522 4
20 2
9±2
10 2U
21 3
22±423 6
19 4
11±33 b
Abbreviations are: PLA, placebo; ENA, enalaprilat; NIP, nitroprusside;
Ang II, angiotensin II; ACE, ACE activity; PRA, plasma renin activity.
P < 0.05 compared to time corresponding PLA
b P < 0.05 compared to time corresponding ENA
fractional sodium excretion (P = 0.004). Proteinuria during
angiotensin II was not significantly different from the correspond-
ing placebo periods, suggesting a complete reversal of the acute
antiproteinuric response of ACE inhibition. However, the in-
crease in proteinuria during angiotensin II compared to the
preceding enalaprilat periods did not prove to be significantly
different due to a great variability in the angiotensin II response.
This analysis on the proteinuria response to angiotensin II may be
confounded by the fact that two patients repeatedly showed no
antiproteinuric response to enalaprilat. Repeated analysis exclud-
ing these two non-responders, however, still showed similar
results. The two non-responders showed similar blood pressure
and renal hemodynamic responses compared to the other patients
during concomitant angiotensin II infusion, whereas proteinuria
remained unchanged.
Correlations
The change in proteinuria during ACE inhibition and nitro-
prusside was related with the accompanying change in MAP in the
last clearance period (N = 18, r = 0.54, P < 0.05). No relation
could be observed with the changes in renal hemodynamics. The
change in proteinuria during angiotensin II infusion was not
related to changes in blood pressure or renal hemodynamics.
Prolonged ACE inhibition
During prolonged treatment with 10 mg enalapril o.i.d. in eight
patients, proteinuria fell gradually by —18.9 8.7% after one day
of treatment, —32.2 8.2% after seven days treatment, and
—43.3 9.1% after 28 days treatment. The decrease in MAP was
—6.7 3.3% after one day and —10.4 1.9% after seven days,
and remained stable by —10.8 2.4% after 28 days of treatment.
Creatinine clearance did not change during continued ACE
inhibition.
Discussion
In the present study enalaprilat as well as nitroprusside acutely
reduced blood pressure and proteinuria to a similar extent,
whereas only enalaprilat induced a renal efferent vasodilatation.
These data suggest that the acute lowering of proteinuria during
single dose ACE inhibition is mediated by reduction in blood
pressure, rather then by its specific renal hemodynamic effects.
Exogenous angiotensin II infusion completely reversed the blood
pressure and renal hemodynamic effect of acute ACE inhibition,
whereas the acute antiproteinuric response of ACE inhibition was
non-significantly reversed.
The acute effects of ACE inhibition compare well to those of
previous reports in non-diabetic and diabetic patients with pro-
teinuria. A recent study from our department showed that infu-
sion of 10 mg enalaprilic acid induced a placebo-corrected
decrease in blood pressure of 11%, an increase in ERPF of 30%,
a decrease in FF of 30%, and a fall in proteinuria of 15% in
non-diabetic patients with proteinuria [10]. Other studies show a
reduction of proteinuria of approximately 20 to 25% during single
dose ACE inhibition [12—141. These studies were not placebo-
controlled, but the numbers are in accordance with our non-
placebo corrected data. The observed changes in MAP, FF, and
proteinuria during placebo infusion, which may be explained by
the sustained supine position or diurnal rhythm [23], emphasizes
the importance of a placebo-controlled study design. To date no
reports on the effects of nitroprusside in nephrotic patients have
been presented. The potent and generalized vasodilatation of
nitroprusside resulted in a lowering of blood pressure without
specific renal hemodynamic effects. By comparing the effects of
the two antihypertensives, one with and one without renal hemo-
dynamic effects, we are the first to differentiate whether systemic
or renal hemodynamics mediate the acute lowering of proteinuria
by ACE inhibitors. The combined nitroprusside and ACE inhibi-
tion data clearly show that the acute fall in proteinuria is
associated with a fall in blood pressure, and not with changes in
renal hemodynamics. This acute lowering of proteinuria may thus
be explained by the transmission of a lower systemic blood
pressure into the glomerulus. In that case, however, one might
also expect noticable changes in GFR. Since we could only
demonstrate slight and non-significant changes in GFR during
infusion of enalaprilat and nitroprusside, the techniques used to
measure renal hemodynamics in humans may not be sensitive
enough to detect subtle GFR changes. The mechanism of the
acute fall in proteinuria thus remains as yet unexplained apart
from the fact that it is associated with a fall in blood pressure.
The renal and systemic responses to exogenous angiotension II
in the present study are opposite to the effects of acute ACE
inhibition and as such in accordance with those found in several
animal [15—19] and human studies [11, 24, 25]. Reversing the
blood pressure lowering effect of ACE inhibition through angio-
tensin II should have induced a return of proteinuria to pretreat-
ment values. Although this did indeed happen in some patients,
the acute antiproteinuric response to ACE inhibition could not be
statistically significantly reversed by angiotensin II. It may well be
that systemic delivery of angiotensin II to the kidney, besides renal
efferent vasoconstriction, also constricts the preglomerular vessel
considerably, thus preventing the rise in blood pressure to fully
affect the intraglomerular pressure [26]. Both Heeg et al [111 and
Loon et al [25] found a reduced GFR together with an increased
FF during angiotensin II infusion, reflecting renal afferent and
efferent vasoconstriction. In contrast, we found an increase in
GFR and FF during angiotensin II infusion, reflecting predomi-
nantly renal efferent vasoconstriction. This may explain why the
acute antiproteinuric response of ACE inhibition was influenced
by angiotensin II in some of our patients. In retrospect, exogenous
infusion of angiotensin II may not have been the ideal tool to test
the blood pressure dependence of the acute antiproteinuric effect,
since it may also have induced renal hemodynamic changes
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different from those of intrarenal angiotensin II perturbations
[27].
The prevailing hypothesis to explain the antiproteinuric effect
of chronic ACE inhibition suggests a relation between reduction
in proteinuria and the ACE inhibition induced changes in renal
hemodynamics [9]. The predominantly postglomerular vasodila-
tation by ACE inhibitors which results in a decrease of intraglo-
merular pressure has been suggested to be responsible for lower-
ing of proteinuria [5, 6]. We conclude that in humans the
short-term antiproteinuric effect of ACE inhibition appears to be
mediated by blood pressure reduction and does not require the
specific renal hemodynamic effects of ACE inhibition. This acute
reduction of proteinuria is relatively small (20%), whereas a
gradual increase of the antiproteinuric response to approximately
50% occurs during prolonged ACE inhibition in our patients. As
was demonstrated previously, this gradual increase is not associ-
ated with any further change in blood pressure or renal hemody-
namics [10]. Together with the results of the angiotensin II
infusion during long-term ACE inhibition [11], this leads us to
hypothesize that the long-term effects are mediated by tissue
angiotensin II or by slowly appearing structural effects on the
glomerular filtration barrier. This is supported by several studies
which show that long-term ACE inhibition has beneficial effects
on glomerular permselectivity [28—32]. Although the specific
renal hemodynamic changes of ACE inhibition initially play no
role in the antiproteinuric response, it may well be that they are
still important because such hemodynamic changes may form the
basis and may gradually induce the structural changes of the
glomerular filtration barrier. This may also explain why other
antihypertensives without a specific renal hemodynamic profile
like ACE inhibitors do not lower proteinuria beyond their initial
small effect. Indeed, several studies suggest a relation between
renal hemodynamic conditions and structural alterations. It has
been shown that angiotensin Ii induced intrarenal vasoconstric-
tion is associated with early growth response genes [33] and
increased hyperproliferative responses to mechanical strain [34].
Further studies should clarify whether the antiproteinuric mech-
anism of ACE inhibition requires a renal hemodynamically me-
diated phase that gradually induces renal structural changes that
prevent the abundant passage of proteins.
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